whole lung allergen challenge

Phase 1Biologic

TThe Cleveland Clinic

whole lung allergen challenge is one of 22 biologic programs targeting Asthma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

AsthmaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 3

Atrovent

Boehringer Ingelheim

Preclinical

5 4

Arcoxia

Symbicort

6 6

Atrovent

Boehringer Ingelheim

Preclinical

2 7

Aciphex

Akero Therapeutics

Preclinical

2 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 9

Tylenol

KKenvue Brands

Preclinical

1 10

DUPIXENT

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

Asthma Inflammation Research

Enrolling by invitation·TThe Cleveland Clinic·Phase 1·NCT01536522·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for whole lung allergen challenge. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — whole lung allergen challenge compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for whole lung allergen challenge. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Cleveland Clinic

whole lung allergen challenge

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News